Conference Coverage

Advances in ankylosing spondylitis hailed as rheumatology’s story of the year

Publish date: March 9, 2020

 

REPORTING FROM RWCS 2020

Pages

Recommended Reading

Certolizumab may reduce uveitis flares, axSpA disease activity
MDedge Rheumatology
Evidence grows for early axSpA treatment, uveitis flare prevention
MDedge Rheumatology
FDA approves infliximab-axxq for numerous indications
MDedge Rheumatology
Repeat LTBI testing best in patients taking biologics with new risk factors
MDedge Rheumatology
TNFi treatment shows hint of slowing axial spondyloarthritis radiographic progression
MDedge Rheumatology
In rheumatology, biosimilars are flatlining. Why?
MDedge Rheumatology
Anti–TNF-alpha nonresponse in axSpA predicted by socioeconomic, patient-reported factors
MDedge Rheumatology
New guideline offers recommendations for reproductive health in patients with rheumatic diseases
MDedge Rheumatology
Meta-analysis highlights safety concerns with interleukin inhibition
MDedge Rheumatology
HLA-B27 status predicts radiographic phenotype of axSpA
MDedge Rheumatology